Cabometyx® In Combination With Nivolumab Shows Durable Survival Benefits At Over Three-Years' Follow-Up In First-Line Advanced Renal Cell Carcinoma

Press/Media

Period13 Feb 2023

Media coverage

1

Media coverage

  • TitleCabometyx® In Combination With Nivolumab Shows Durable Survival Benefits At Over Three-Years' Follow-Up In First-Line Advanced Renal Cell Carcinoma
    Media name/outletMENAFN -Press Releases (English)
    Country/TerritoryJordan
    Date13/02/23
    PersonsMauricio Burotto